BLS Pharmaceuticals Limited (ASX:BLS)
Australia · Delayed Price · Currency is AUD 1.180
-0.025 (-2.07%)
Sep 22, 2026, 4:10 PM AEST
BLS Pharmaceuticals Financials Overview
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Revenue Revenue Growth | 73.91 | 73.91 | 29.28 | 9.64 | 5.3 | 0.46 |
Revenue Growth | 54.13% | 152.42% | 203.66% | 81.97% | 1042.88% | -78.97% |
Gross Profit Gross Profit Growth | 39.48 | 39.48 | 17.03 | 3.72 | 1.57 | 0.13 |
Operating Income Operating Income Growth | 19.55 | 19.55 | 7.72 | -1.13 | -1.82 | -0.45 |
Net Income Net Income Growth | 15.4 | 15.4 | 4.9 | -13.33 | -1.94 | -0.49 |
Earnings Per Share EPS Growth | 0.07 | 0.07 | 0.02 | -0.07 | -0.01 | -0.01 |
EPS Growth | 67.99% | 191.30% | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Wholesale - PCC/USA Wholesale - PCC/USA Growth | 0.55 | 0.55 | 0.7 | 0.89 | 0.04 | - |
Plant Based - UK/EU/JPN/AUS Plant Based - UK/EU/JPN/AUS Growth | 2.47 | 2.47 | 3.05 | 5.44 | 5.11 | 0.46 |
Manufacture/sales - Australia Manufacture/sales - Australia Growth | 71.14 | 71.14 | 24.68 | 3 | - | - |
Unallocated Unallocated Growth | - | - | 0.87 | 0.33 | 0.18 | 0 |
Total Total Growth | 74.16 | 74.16 | 29.3 | 9.66 | 5.34 | 0.47 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Investments Cash & Investments Growth | 13.29 | 13.29 | 7.67 | 1.03 | 3.85 | 0.07 |
Total Debt Total Debt Growth | 8.43 | 8.43 | 1.53 | 0.71 | 0.56 | 0.4 |
Net Cash (Debt) Net Cash Growth | 4.86 | 4.86 | 6.13 | 0.32 | 3.29 | -0.33 |
Net Cash Growth | 117.15% | -20.84% | 1831.58% | -90.34% | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.02 | 0.02 | 0.03 | 0.00 | 0.02 | -0.00 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 5.41 | 5.41 | 6.28 | -3.56 | -1.13 | -0.51 |
Capital Expenditures CapEx Growth | -3.81 | -3.81 | -2.07 | -0.18 | -0.06 | -0.06 |
Free Cash Flow Free Cash Flow Growth | 1.61 | 1.61 | 4.21 | -3.74 | -1.19 | -0.57 |
Free Cash Flow Growth | 467.01% | -61.82% | - | - | - | - |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Gross Margin | 53.42% | 53.42% | 58.17% | 38.53% | 29.55% | 29.10% |
Operating Margin | 26.45% | 26.45% | 26.36% | -11.75% | -34.32% | -97.72% |
Pretax Margin | 20.51% | 20.51% | 16.74% | -134.56% | -36.16% | -106.55% |
Profit Margin | 20.83% | 20.83% | 16.74% | -138.19% | -36.61% | -106.55% |
FCF Margin | 2.17% | 2.17% | 14.37% | -38.77% | -22.45% | -122.27% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 22, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | 17.99 | 13.84 | 18.11 | - | - | - |
P/FCF Ratio | 172.74 | 132.62 | 21.09 | - | - | - |
PS Ratio | 3.75 | 2.88 | 3.03 | 1.06 | 7.18 | 16.57 |